Patent details

Basic Information

Publication number:

EP3350346

PCT Application Number:

EP2016072069

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP167755073

PCT Publication Number:

WO2017046394

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

NOVEL BIOMARKERS AND METHODS OF TREATING CANCER

French Title of Invention:

NOUVEAUX BIOMARQUEURS ET PROCÉDÉS DE TRAITEMENT DU CANCER

German Title of Invention:

NEUARTIGE BIOMARKER UND VERFAHREN ZUR BEHANDLUNG VON KREBS

SPC Number:

Dates

Filing date:

16/09/2016

Grant date:

04/01/2023

EP Publication Date:

25/07/2018

PCT Publication Date:

23/03/2017

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

04/01/2023

EP B1 Publication Date:

04/01/2023

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

16/09/2023

Expiration date:

16/09/2036

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

28/12/2022

 

 

Name:

Astrazeneca AB

Address:

Forskargatan 18, 151 85 Södertälje, Sweden (SE)

Inventor

1

Name:

VALDERAS, Alvaro, Avivar

Address:

United Kingdom (GB)

2

Name:

CRUZALEGUI, Francisco, Humberto

Address:

United Kingdom (GB)

3

Name:

MCEWEN, Robert, Kenneth

Address:

United Kingdom (GB)

4

Name:

HUDSON, Kevin

Address:

United Kingdom (GB)

Priority

Priority Number:

201562219698 P

Priority Date:

17/09/2015

Priority Country:

United States (US)

Classification

IPC classification:

C12Q 1/68;

Publication

European Patent Bulletin

Issue number:

202301

Publication date:

04/01/2023

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages